Testing a new treatment for hard-to-treat T-cell lymphoma

Plain-English translation of NCT07192471 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is a first-in-human study testing a new medication called in people with T-cell lymphoma that has come back or stopped responding to previous treatments. The trial will start by giving some patients low doses of the medication and gradually increase the dose to find the safest and most effective level. The main goal is to understand how safe the medication is, how well it is tolerated, and how it works in the body.

T-cell lymphomas are rare blood cancers that are often very difficult to treat, especially when they return or stop responding to standard therapies. This trial exists to develop a new treatment option for people who have run out of other effective choices.

Do you qualify?

You likely qualify if…

you are 18 years or older and have been diagnosed with T-cell lymphoma (either nodal or cutaneous types)
your lymphoma has come back, stopped responding to treatment, or you could not tolerate previous treatments
you have measurable disease that can be tracked on scans or skin exams
your overall health is reasonably good, with an ability to care for yourself day-to-day
you have adequate blood counts, kidney function, and liver function (your doctor will test these)

You likely don't qualify if…

you have had a bone marrow or stem cell transplant within the past 4 months
you are pregnant, breastfeeding, or planning to become pregnant during the trial
you have an active infection that is currently being treated with antibiotics or antivirals
you have serious heart disease, recent heart attack, or uncontrolled high blood pressure
you have received another experimental drug within the past 2 weeks

What participation looks like

You will visit the clinic regularly to receive the medication and have your health monitored closely through blood tests and imaging scans. The study has two parts: in the first part, doctors will slowly increase doses to find the safest level, and in the second part, more patients will receive doses that were found to be safe. Throughout the trial, your doctor will watch for side effects and measure whether the lymphoma is responding to treatment.

AI-generated summary from trial data · Sep 1, 2026 · Not medical advice

Trial locations(22 sites)

United States

City of Hope, Duarte, California

University of California, Irvine Medical Center - Hematology/Oncology, Orange, California

Stanford University School of Medicine, Stanford, California

Moffit Cancer Center, Tampa, Florida

Emory University Medical Center, Atlanta, Georgia